| |
Dr. Barenholz is Professor of Biochemistry, the Daniel G. Miller
Professor in Cancer Research and the head of the Laboratory of Membrane
and Liposome Research at the Department of Biochemistry, the Hebrew
University-Hadassah Medical School, Jerusalem, Israel. Professor
Barenholz is one of the key inventors of DOXIL, marketed by Johnson
& Johnson as a cancer treatment. Professor Barenholz is the author
of over 300 publications, the editor of two special issues of Chemistry
and Physics of Lipids and co-author of 4 volumes of Handbook of
Nonmedical Applications of Liposomes. He is the co inventor of over
25 worldwide approved patents and the recipient of the Kay Award
for innovation, the Alec D. Bangham Achievement Award and the TEVA
Founders Prize. Dr. Barenholz was doctoral advisor for Elijah Bolotin,
PhD (founder).
Dr. Bogdanov is the principal inventor of PGC nanotechnology and
has been involved with PharmaIN since its inception in 2000. Dr.Bogdanov
is currently Professor of Radiology and Cell Biology at University
of Massachusetts Medical School, Worcester MA. During 1992-2005
Dr. Bogdanov held a position of Associate Professor at Harvard Medical
School/Massachusetts General Hospital, which he joined in 1991 following
a post-doctoral fellowship at the Webster Center for Biological
Science, Amherst College. He has received numerous academic awards
and is the author of over 80 peer-reviewed papers and ten patents.
Dr. Lippard holds the Arthur Amos Noyes Chair and is former Head
of the Department of Chemistry at the Massachusetts Institute of
Technology. Professor Lippard's research studies biological interactions
involving metal ions, focusing on reactions and physical and structural
properties of metal complexes. This research spans the fields of
inorganic and biological chemistry. Dr. Lippard is affiliated with
MIT's Center for Cancer Research and is well known for his work
on the mechanism of the anti-cancer drug cisplatin. He has received
many fellowships and prizes, including the 2004 National Medal of
Science, election to the National Academy of Sciences, the National
Institute of Medicine, and the American Academy of Arts and Sciences.
Dr. Lippard is the author of more than 670 articles in professional
and scholarly journals and two textbooks, including "Principles
of Bioinorganic Chemistry." He is also an associate editor of the
Journal of the American Chemical Society and holds several U.S.
and foreign patents.
Dr. Perfetti is Medical Director, Global Development Leader, Department
of Medical Sciences, Amgen Inc., and also Associate Professor of
Medicine, University of California at Los Angeles (UCLA). Prior
to joining Amgen in 2004 he was Director, Diabetes Research Laboratory
at Cedars-Sinai Medical Center and Co-Director, Islet Transplantation
Program, City of Hope, Duarte, CA. Dr. Perfetti has received
numerous awards and has published extensively in the field of diabetes
research, including GLP-1 and islet/beta cell biology.
|
|
